19. Pretomanid

Tuberculosis
(Centers for Disease Control and Prevention)

Active ingredient: pretomanid 
Disease: drug-resistant tuberculosis 
Peak sales estimate: n/a 
Approved: Aug. 14, 2019
Company: The Global Alliance for TB Drug Development 

The scoop: The FDA greenlighted Pretomanid as an add-on drug to the antibiotic linezolid and Johnson & Johnson’s tuberculosis drug Sirturo (bedaquiline) for the treatment of a “limited and specific” population of adults with drug-resistant TB. Specifically, it is approved for patients with multidrug-resistant tuberculosis, which is resistant to the two most powerful anti-TB drugs, and extensively drug-resistant tuberculosis, which is resistant to the four main drugs used to treat the disease. Pretomanid is the second drug to score approval under the Limited Population Pathway for Antibacterial and Antifungal Drugs, which was created to spur the development of drugs for infections that do not have effective treatments. Of the 10 million people who contracted tuberculosis in 2017, the World Health Organization estimated that 558,000 of them developed multidrug-resistant TB. — Amirah Al Idrus 

19. Pretomanid

Suggested Articles

With case counts surging and top officials infected, the U.K. is joining the testing for Gilead Sciences' much-hyped antiviral candidate remdesivir.

By redeploying staff, the FDA thinks it can respond to COVID-19-related requests and review protocols within 24 hours of receipt.

The partners leveraged their proximity to the initial outbreak and experience with SARS and MERS to build up a library of neutralizing antibodies.